DEXKETOPROFEN
Breast Cancer Patients Receiving Chemotherapy
Setenay BatırSmall moleculeN/AActive
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 89/ 100
Competitive context
3 Active assets in the Breast Cancer Patients Receiving Chemotherapy cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
NEPENTHE Setenay Batır | N/A | D |
METAMIZOLE Setenay Batır | N/A | D |
LAVENDER OIL Setenay Batır | N/A | D |
Same molecule, other indications
DEXKETOPROFEN is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →